drugset / Trial / NCT04648202
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
Timeline
- Start
- 2020-11-18
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FS120 | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |